Literature DB >> 26301175

Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Daniel C Javitt1.   

Abstract

Entities:  

Keywords:  D-serine; NMDA receptor; Schizophrenia; antipsychotics; atypical antipsychotic; cognitive dysfunction; cognitive therapy; dopamine; dopamine receptor; glutamate; glycine; glycine transport inhibitor; negative symptoms; neuromodulation; positive symptoms; psychosis; serotonin receptor; transcranial direct current stimulation; typical antipsychotic

Year:  2015        PMID： 26301175      PMCID： PMC4540407          DOI： 10.1007/s40501-014-0010-9

Source DB:  PubMed          Journal:  Curr Treat Options Psychiatry


× No keyword cloud information.
  94 in total

1.  Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia.

Authors:  René Gysin; Rudolf Kraftsik; Olivier Boulat; Pierre Bovet; Philippe Conus; Emily Comte-Krieger; Andrea Polari; Pascal Steullet; Martin Preisig; Tanja Teichmann; Michel Cuénod; Kim Q Do
Journal:  Antioxid Redox Signal       Date:  2010-10-30       Impact factor: 8.401

Review 2.  Using ECT in schizophrenia: a review from a clinical perspective.

Authors:  Iannis M Zervas; Christos Theleritis; Costantin R Soldatos
Journal:  World J Biol Psychiatry       Date:  2011-04-12       Impact factor: 4.132

Review 3.  Metabotropic glutamate receptors as therapeutic targets for schizophrenia.

Authors:  Paige N Vinson; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2011-05-19       Impact factor: 5.250

4.  Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia.

Authors:  Tamara Friedman; Pejman Sehatpour; Elisa Dias; Megan Perrin; Daniel C Javitt
Journal:  Biol Psychiatry       Date:  2011-12-21       Impact factor: 13.382

5.  Folate supplementation in schizophrenia: a possible role for MTHFR genotype.

Authors:  Michele Hill; Kelsey Shannahan; Sarah Jasinski; Eric A Macklin; Lisa Raeke; Joshua L Roffman; Donald C Goff
Journal:  Schizophr Res       Date:  2011-02-21       Impact factor: 4.939

6.  Hippocampal plasticity in response to exercise in schizophrenia.

Authors:  Frank-Gerald Pajonk; Thomas Wobrock; Oliver Gruber; Harald Scherk; Dorothea Berner; Inge Kaizl; Astrid Kierer; Stephanie Müller; Martin Oest; Tim Meyer; Martin Backens; Thomas Schneider-Axmann; Allen E Thornton; William G Honer; Peter Falkai
Journal:  Arch Gen Psychiatry       Date:  2010-02

Review 7.  Clozapine: balancing safety with superior antipsychotic efficacy.

Authors:  Herbert Y Meltzer
Journal:  Clin Schizophr Relat Psychoses       Date:  2012-10

8.  Homocysteine reduces NMDAR desensitization and differentially modulates peak amplitude of NMDAR currents, depending on GluN2 subunit composition.

Authors:  Andrew D Bolton; Marnie A Phillips; Martha Constantine-Paton
Journal:  J Neurophysiol       Date:  2013-07-17       Impact factor: 2.714

9.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Authors:  Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

Review 10.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711
View more
  7 in total

1.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

2.  Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.

Authors:  Migyung Lee; Andrea Balla; Henry Sershen; Pejman Sehatpour; Peter Lakatos; Daniel C Javitt
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

3.  Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.

Authors:  Thomas Papouin; Jaclyn M Dunphy; Michaela Tolman; Kelly T Dineley; Philip G Haydon
Journal:  Neuron       Date:  2017-05-04       Impact factor: 17.173

4.  Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.

Authors:  Henry Sershen; Audrey Hashim; David S Dunlop; Raymond F Suckow; Tom B Cooper; Daniel C Javitt
Journal:  Neurochem Res       Date:  2016-02-08       Impact factor: 3.996

5.  Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.

Authors:  Iris E Sommer; Shiral S Gangadin; Lot D de Witte; Sanne Koops; C van Baal; Sabine Bahn; Hemmo Drexhage; N E M van Haren; Wim Veling; R Bruggeman; Peter Martens; Sybren Wiersma; Selene R T Veerman; Koen P Grootens; Nico van Beveren; Rene S Kahn; Marieke J H Begemann
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

6.  Time to Re-focus onto Cognitive Symptoms in Schizophrenia.

Authors:  M S Reddy; S V Mythri
Journal:  Indian J Psychol Med       Date:  2016 Mar-Apr

7.  Persistent negative symptoms in individuals at Ultra High Risk for psychosis.

Authors:  Alison R Yung; Barnaby Nelson; Patrick D McGorry; Stephen J Wood; Ashleigh Lin
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.